With the historic achievement, two out of the five Cuban vaccine candidates, Soberana 02 with 91.2% and Abdala with 92.28% efficacy, are among the top 5 most effective anti-COVID-19 vaccines worldwide

Two new vaccines, both developed in Cuba, have shown remarkable efficacy in clinical trials. It is crucial to remember that Cuba developed these vaccines even as it continues to suffer under the crippling blockade imposed by the US.

Today we look at the UN’s annual report on Children and Armed Conflict, the final trials of Cuba’s Abdala and Soberana 02 vaccines, and more

The Abdala vaccine showed 92.28% efficacy with three doses during the third phase of clinical trials and the Soberana 02 vaccine showed 62% efficacy with just two of its three doses

In previous trials, the Soberana 02 vaccine candidate generated antibody response in about 80% of the people who were administered two doses

Amid growing accusations of vaccine hoarding by global north countries and patents blocking vaccine production, researcher and filmmaker Beth Geglia writes about the importance of supporting Cuba’s vaccines which will be available to all

In this final and decisive phase of trials, the objective is to evaluate the efficacy, safety and immunogenicity of Soberana 02. If the vaccine produces fruitful results, Cuba will become the first country in the Latin American and the Caribbean region to develop its own vaccine

Cuba is the only country in the Latin American and the Caribbean region that is working to develop its own vaccines against COVID-19. The country has four vaccine candidates. Two of them, Soberana 02 of the Finlay Vaccine Institute (IFV) and Abdala of the Center for Genetic Engineering and Biotechnology (CIGB), will begin the third phase of clinical trials in March

Cuba’s vaccine candidate is the first from the Latin America and the Caribbean region and marks a continuation of its pioneering work in combating COVID-19 across the world